Sciclone Pharmaceuticals, Inc. (SCLN) Tops Q3 EPS by 2c; Authorizes $20M Buyback
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Price: $11.15 --0%
Financial Fact:
Diluted net income per share: 0.19
Today's EPS Names:
SFST, VLTO, CLIR, More
Financial Fact:
Diluted net income per share: 0.19
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q3 EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $37.4 million versus the consensus estimate of $37.5 million.
SciClone announced that its Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $20 million of its outstanding common stock over 24 months.
SciClone announced that its Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $20 million of its outstanding common stock over 24 months.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zoned Properties, Inc. (ZDPY) Announces $1M Share Buyback
- Fiserv (FI) Tops Q1 EPS by 9c; Boosts outlook
- NextEra Energy (NEE) Tops Q1 EPS by 16c, provides guidance
Create E-mail Alert Related Categories
Earnings, Stock BuybacksRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
